Back to News
NIH NCI SBIR Phase I Award
“Porem ipsum dolor sit amet, consectetur adipiscing elit. Nunc vulputate libero et velit interdum, ac aliquet odio mattis. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos.”
We are proud to announce that General Proximity has been awarded a NIH NCI SBIR Phase I grant. This $400k grant will drive our efforts to develop groundbreaking treatments targeting Triple Negative Breast Cancer (TNBC), one of the most challenging and aggressive forms of breast cancer.
This award represents a pivotal step forward in our mission to innovate and develop transformative treatments for patients facing critical unmet needs.
